NRXP Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.810

Open

1.790

VWAP

1.80

Vol

138.72K

Mkt Cap

57.69M

Low

1.780

Amount

249.01K

EV/EBITDA(TTM)

--

Total Shares

31.87M

EV

60.57M

EV/OCF(TTM)

--

P/S(TTM)

--

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

Show More

Events Timeline

(ET)

2026-03-09

07:20:00

HOPE Therapeutics Opens New Clinic in Palm Beach, FL

2026-03-02 (ET)

2026-03-02

07:20:00

NRx Pharmaceuticals Appoints Prof. Joshua Brown as Chief Medical Innovation Officer

2026-02-17 (ET)

2026-02-17

07:20:00

NRx Pharmaceuticals Completes FDA Meeting, Plans to File for NRX-100 New Drug Approval

2026-01-14 (ET)

2026-01-14

07:10:00

NRx Pharmaceuticals Licenses Real World Evidence from 70,000 Patients

2026-01-05 (ET)

2026-01-05

07:00:00

NRx Pharmaceuticals Partners with neurocare Group to Establish Nationwide Neuroplastic Care Network

News

Newsfilter

02-17Newsfilter

NRx and FDA Meeting Advances New Drug Application for NRX-100

Globenewswire

01-16Globenewswire

NRx Pharmaceuticals Sets Date for 2025 Annual Meeting and Proposal Deadline

stocktwits

01-14stocktwits

NRx Pharmaceuticals Licenses RWE from 70,000 Patients to Support NRX-100 FDA Approval

Globenewswire

01-14Globenewswire

NRX Pharmaceuticals' NRX-100 Receives FDA Fast Track Designation Supported by 70,000 Patient Real-World Evidence

Benzinga

BTIG Raises Hudson Pacific Price Target to $26

Globenewswire

2025-12-18Globenewswire

NRx Pharmaceuticals Repays $5.4 Million Debt, Positions for Accelerated Growth in 2026

3 Analyst Rating

Wall Street analysts forecast NRXP stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

37.67

High

48.00

Current: 0.000

Low

25.00

Averages

37.67

High

48.00

H.C. Wainwright

Buy

maintain

$40 -> $45

AI Analysis

2026-03-03

Reason

H.C. Wainwright

Price Target

$40 -> $45

AI Analysis

2026-03-03

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on NRx Pharmaceuticals to $45 from $40 and keeps a Buy rating on the shares. The firm says the type C FDA meeting "provides a clear" application pathway for NRX-100. This is "supported by real-world evidence and a broader proposed indication, significantly de-risking the program," the analyst tells investors in a research note. H.C. Wainwright expanded the addressable population for NRX-100 and increased its risk-adjusted NRX-100 valuation to $15 per share from $10.

Ascendiant

Buy

maintain

$47 -> $48

2026-01-02

Reason

Ascendiant

Price Target

$47 -> $48

2026-01-02

maintain

Buy

Reason

Ascendiant raised the firm's price target on NRx Pharmaceuticals to $48 from $47 and keeps a Buy rating on the shares following the Q3 report in November. The firm sees "major opportunities" for NRX-100 and NRX-101, which should both have FDA action dates in 2026. The firm sees these news events driving NRx shares in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NRXP

Unlock Now

Valuation Metrics

The current forward P/E ratio for NRX Pharmaceuticals Inc (NRXP.O) is 184.51, compared to its 5-year average forward P/E of 4.12. For a more detailed relative valuation and DCF analysis to assess NRX Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

4.12

Current PE

184.51

Overvalued PE

31.51

Undervalued PE

-23.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.53

Current EV/EBITDA

24.25

Overvalued EV/EBITDA

5.44

Undervalued EV/EBITDA

-4.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.18

Current PS

1.25

Overvalued PS

0.54

Undervalued PS

-0.17

Financials

AI Analysis

Annual

Quarterly

Whales Holding NRXP

Trading Trends

People Also Watch

Frequently Asked Questions

What is NRX Pharmaceuticals Inc (NRXP) stock price today?

The current price of NRXP is 1.795 USD — it has decreased -0.83

What is NRX Pharmaceuticals Inc (NRXP)'s business?

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.

What is the price predicton of NRXP Stock?

Wall Street analysts forecast NRXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXP is37.67 USD with a low forecast of 25.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NRX Pharmaceuticals Inc (NRXP)'s revenue for the last quarter?

NRX Pharmaceuticals Inc revenue for the last quarter amounts to 242.00K USD, decreased

What is NRX Pharmaceuticals Inc (NRXP)'s earnings per share (EPS) for the last quarter?

NRX Pharmaceuticals Inc. EPS for the last quarter amounts to -0.26 USD, increased 73.33

How many employees does NRX Pharmaceuticals Inc (NRXP). have?

NRX Pharmaceuticals Inc (NRXP) has 0 emplpoyees as of March 11 2026.

What is NRX Pharmaceuticals Inc (NRXP) market cap?

Today NRXP has the market capitalization of 57.69M USD.